Certara Overview
- Status
-
Public
- Employees
-
1,114
- Stock Symbol
-
CERT
- Investments
-
17
- Share Price
-
$20.19
- (As of Thursday Closing)
Certara General Information
Description
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA and other regions, of which a majority of revenue is derived from the United States.
Contact Information
Website
www.certara.com
Formerly Known As
Tripos
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Decision/Risk Analysis
Stock Exchange
NAS
Primary Office
- Overlook Center
- Suite 101
- Princeton, NJ 08540
- United States
+1 (415) 000-0000
Certara Timeline
Certara Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $20.19 | $20.36 | $16.18 - $45.48 | $3.23B | 160M | 503K | -$0.06 |
Certara Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 3,554,703 | 4,416,264 | 5,508,372 | |
| Revenue | 313,601 | 286,104 | 243,530 | 208,511 |
| EBITDA | 66,470 | 58,577 | 17,868 | 60,413 |
| Net Income | (9,840) | (13,266) | (49,397) | (8,926) |
| Total Assets | 1,501,749 | 1,511,730 | 1,269,400 | 1,037,069 |
| Total Debt | 306,956 | 308,380 | 299,373 | 401,379 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Certara Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Certara Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug d
Other Healthcare Technology Systems
Princeton, NJ
1,114
As of 2021
00000
00000000000
00000
000000
sequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
0000000000000
Menlo Park, CA
000
As of 0000
00000
000000000
00000
000000
scing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veni
00000 0000000000 0000000000 0000000
Simsbury, CT
00
As of 0000
0000000000
Add Comparison
Certara Competitors (11)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pacific Biosciences | Formerly VC-backed | Menlo Park, CA | 000 | 00000 | 000000000 | 00000 |
| 000000 00000000 00 | Corporation | Simsbury, CT | 00 | 0000000000 | ||
| 00000000 000000000 | Private Equity-Backed | Montreal, Canada | 00 | 00000000. 00 | ||
| 0000 0000000000000 | Venture Capital-Backed | Palo Alto, CA | 00 | 000.00 | 000000000 - | 000.00 |
| 0000ö000000 | Formerly VC-backed | New York, NY | 000 | 00000 | 00000000000 | 00000 |
Certara Patents
Certara Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210032682-A1 | Methods and apparatus for quantifying protein abundance in tissues via cell free ribonucleic acids in liquid biopsy | Pending | 28-Mar-2018 | 0000000000 | |
| JP-2022513549-A | Methods and apparatus for quantifying protein abundance in tissues mediated by cell-free ribonucleic acid in liquid biopsy | Pending | 28-Mar-2018 | 000000000 | |
| EP-3775260-A4 | Methods and apparatus for quantifying protein abundance in tissues via cell free ribonucleic acids in liquid biopsy | Pending | 28-Mar-2018 | 000000000 | 0 |
| EP-3775260-A1 | Methods and apparatus for quantifying protein abundance in tissues via cell free ribonucleic acids in liquid biopsy | Pending | 28-Mar-2018 | 0000000000 | |
| CA-3094724-A1 | Methods and apparatus for quantifying protein abundance in tissues via cell free ribonucleic acids in liquid biopsy | Pending | 28-Mar-2018 | C12Q1/6886 |
Certara Executive Team (27)
Certara Board Members (24)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 000000000 00 | Self | Board Member | 000 0000 |
| 0000000 0000000 | Certara | Board Member | 000 0000 |
| 0000 000000 | Certara | Board Member | 000 0000 |
| 0000 000 | EQT | Board Member | 000 0000 |
| 00000 0000000 000 | Certara | Chairman & Board Member | 000 0000 |
Certara Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Certara Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Certara Investments & Acquisitions (17)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 00 | 03-Jan-2022 | 0000000000 | 00.000 | Other Healthcare Technology Systems | 0000000 0 |
| 00000000 00 | 01-Oct-2021 | 0000000000 | 00000 | Business/Productivity Software | 0000000 0 |
| 0000000 00000 | 10-Jun-2021 | 0000000000 | Other Healthcare Services | 000000 00 | |
| 000000! | 02-Mar-2021 | 0000000000 | 00.000 | Decision/Risk Analysis | 000000000 |
| Pirana | 13-Sep-2018 | Buyout/LBO | Business/Productivity Software | 000000 00 |
Certara Subsidiaries (7)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Pinnacle 21 | Business/Productivity Software | Blue Bell, PA | 2011 |
| 0000000000 0000000 | Other Healthcare Technology Systems | Ann Arbor, MI | 0000 |
| 00000000 | Business/Productivity Software | Berlin, Germany | 0000 |
| 0000000 0000000 00 | Other Healthcare Services | Kidlington, United Kingdom | 0000 |
| 000000! | Decision/Risk Analysis | Hilversum, Netherlands | 0000 |
Certara Exits (3)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000 | 30-Apr-2002 | 00000 00000 00 | 00.00 | Completed |
|
| 0000000 | 01-May-2000 | 0000 00000 | Completed |
|
|
| Arena Pharmaceuticals | 22-Feb-1999 | Later Stage VC | 0000 | Completed |
|